We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of In Vitro Cytotoxic Potential of Avarol towards Human Cancer Cell Lines and In Vivo Antitumor Activity in Solid Tumor Models.
- Authors
Stanojkovic, Tatjana P.; Filimonova, Marina; Grozdanic, Nadja; Petovic, Slavica; Shitova, Anna; Soldatova, Olga; Filimonov, Alexander; Vladic, Jelena; Shegay, Petr; Kaprin, Andrey; Ivanov, Sergey; Nikitovic, Marina
- Abstract
The goal of this study was to determine the activity in vitro and in vivo of avarol, a sesquiterpene hydroquinone originating from the Dysidea avara sponge from the south Adriatic Sea, against different cancer cell lines and two types of mouse carcinoma. To investigate the in vitro cytotoxicity, a human cervix adenocarcinoma cell line (HeLa), human colon adenocarcinoma (LS174), human non-small-cell lung carcinoma (A549), and a normal human fetal lung fibroblast cell line (MRC-5) were used. The in vivo antitumor activity was investigated against two transplantable mouse tumors, the Ehrlich carcinoma (EC) and cervical cancer (CC-5). The effect of avarol on cancer cell survival, which was determined by the microculture tetrazolium test, confirmed a significant in vitro potency of avarol against the investigated cell lines, without selectivity towards MRC-5. The highest cytotoxicity was exhibited against HeLa cancer cells (10.22 ± 0.28 μg/mL). Moreover, potent antitumor activity against two tumor models was determined, as the intraperitoneal administration of avarol at a dose of 50 mg/kg resulted in a significant inhibition of tumor growth in mice. After three administrations of avarol, a 29% inhibition of the EC growth was achieved, while in the case of CC-5, a 36% inhibition of the tumor growth was achieved after the second administration of avarol. Therefore, the results indicate that this marine sesquiterpenoid hydroquinone could be a promising bioactive compound in the development of new anticancer medicine.
- Subjects
CELL lines; CANCER cells; ANTINEOPLASTIC agents; NON-small-cell lung carcinoma; HELA cells; TUMOR growth
- Publication
Molecules, 2022, Vol 27, Issue 24, p9048
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules27249048